These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 17761978

  • 1. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
    Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D.
    J Clin Oncol; 2007 Sep 01; 25(25):3945-51. PubMed ID: 17761978
    [Abstract] [Full Text] [Related]

  • 2. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G.
    J Clin Oncol; 2006 May 01; 24(13):2044-51. PubMed ID: 16648504
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
    Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE.
    J Clin Oncol; 2004 Dec 01; 22(23):4683-90. PubMed ID: 15570070
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.
    J Clin Oncol; 2009 Aug 01; 27(22):3664-70. PubMed ID: 19451428
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ.
    J Clin Oncol; 2005 Dec 20; 23(36):9377-86. PubMed ID: 16361638
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
    Dowlati A, Subbiah S, Cooney M, Rutherford K, Mekhail T, Fu P, Chapman R, Ness A, Cortas T, Saltzman J, Levitan N, Warren G.
    Lung Cancer; 2007 Jun 20; 56(3):377-81. PubMed ID: 17328989
    [Abstract] [Full Text] [Related]

  • 7. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):533-41. PubMed ID: 18398095
    [Abstract] [Full Text] [Related]

  • 8. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1049-57. PubMed ID: 19608997
    [Abstract] [Full Text] [Related]

  • 9. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.
    J Clin Oncol; 2009 Oct 01; 27(28):4787-92. PubMed ID: 19720897
    [Abstract] [Full Text] [Related]

  • 10. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
    Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA.
    Lung Cancer; 2008 May 01; 60(2):200-7. PubMed ID: 18045731
    [Abstract] [Full Text] [Related]

  • 11. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
    Sorensen M, Lassen U, Palshof T, Jensen BB, Johansen J, Jensen PB, Langer SW.
    Lung Cancer; 2008 May 01; 60(2):252-8. PubMed ID: 18036701
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
    Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U.
    Lung Cancer; 2007 Jan 01; 55(1):109-13. PubMed ID: 17097191
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE.
    J Clin Oncol; 2008 Apr 10; 26(11):1886-92. PubMed ID: 18398154
    [Abstract] [Full Text] [Related]

  • 14. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T.
    J Natl Cancer Inst; 2001 Feb 21; 93(4):300-8. PubMed ID: 11181777
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 21; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.
    Gynecol Oncol; 2007 Sep 21; 106(3):596-603. PubMed ID: 17597196
    [Abstract] [Full Text] [Related]

  • 17. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.
    Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K.
    J Clin Oncol; 2007 Nov 20; 25(33):5233-9. PubMed ID: 18024869
    [Abstract] [Full Text] [Related]

  • 18. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
    Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C.
    J Clin Oncol; 2005 Oct 01; 23(28):6854-64. PubMed ID: 16192577
    [Abstract] [Full Text] [Related]

  • 19. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
    Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S.
    J Thromb Haemost; 2004 Aug 01; 2(8):1266-71. PubMed ID: 15304029
    [Abstract] [Full Text] [Related]

  • 20. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G.
    J Clin Oncol; 2007 May 20; 25(15):2086-92. PubMed ID: 17513814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.